IMMX — Immix Biopharma, Inc.

Is IMMX overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Biotechnology

Overbought As of August 19, 2026

Immix Biopharma, Inc. (IMMX) currently reads Overbought on the MarketMoodz overbought/oversold meter, as of August 19, 2026. The Healthcare name (Biotechnology) last closed at $13.19. The rating moved from Neutral to Overbought on August 18, 2026.

See all overbought Healthcare stocks →

AI analysis

Immix Biopharma, Inc. (IMMX) is a clinical-stage biopharma whose equity value is driven primarily by pipeline progress and partnering/financing outcomes rather than recurring revenue. With sector dynamics that favor biologics and specialized CDMO/CRO services, the company benefits from favorable thematic tailwinds, but it faces typical small-cap biotech risks: high cash burn, potential dilution, trial/regulatory binary events, and limited liquidity. The near-term market backdrop is neutral, leaving company-specific catalysts as the main determinants of price movement over the coming weeks.

Key factors

  • Clinical-stage pipeline with potential binary catalysts (trial readouts / regulatory milestones) that can drive large percentage moves in share price
  • Sector tailwinds for biologics, gene-therapy suppliers and specialized CDMO/CRO demand that can improve commercial outlook for companies with biologics assets
  • Limited revenue profile typical of early-stage biotech, which focuses upside on successful clinical or partnering events rather than steady cash flow
  • Acquisition and M&A multiple environment in biotech remains elevated, increasing takeover/partnering optionality for attractive rare-disease or oncology assets
  • Low current public attention and muted macro headlines reduce short-term volatility from broad market moves, allowing idiosyncratic catalysts to dominate

Risks

  • Clinical trial failure or safety/regulatory setbacks that would materially impair value
  • Cash runway and financing/dilution risk if capital markets remain constrained or if a larger-than-expected raise is required
  • Limited or no near-term revenue; dependence on milestone, partnering, or financing events for upside
  • Low trading liquidity and higher bid/ask spreads can amplify downside in stress scenarios
  • Competitive risk from larger pharma/biotech players or alternative therapeutic modalities
  • Regulatory and reimbursement uncertainty that could compress long-term commercial potential
  • Negative sentiment or litigation exposure related to digital-health or data/privacy themes in the broader sector (indirect contagion risk)

See today's live rating, score and targets

Members see the live hourly rating for IMMX — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.